ArticleResearch and practice in thrombosis and haemostasis2025
Emicizumab, the factor VIII mimetic bispecific monoclonal antibody: effects on thrombin generation and thromboelastometry.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emicizumab is used for prophylaxis of patients with hemophilia A. Because it is used at a fixed dose that is not based on laboratory testing, evaluation of its activity is occasionally needed. Global coagulation procedures such as thrombin generation assays (TGAs) or thromboelastometry are obvious candidates for testing. Information on the significance of TGA or thromboelastometry parameters in patients treated with emicizumab is limited. Objectives: We performed a 2-step study to gain insight into the pattern of variation of TGA or thromboelastometry results in patients treated with emicizumab. Methods: The first experiment was an Results: While TGA thrombin peak and endogenous thrombin potential (ETP) showed good dose-response with emicizumab concentrations, lag time and time-to-peak did not. The best TGA condition in terms of reagent composition was 1 pM tissue factor plus 1 μM phospholipids. There was a strong correlation between thrombin peak or ETP and emicizumab concentrations. The correlation was highly significant for thromboelastometry clotting time, but only when the procedure was performed without exogenous triggers. Based on the above correlations, we estimated the value of TGA or thromboelastometry parameters corresponding to the critical values of 40 or 80 μg/mL emicizumab. Conclusion: TGA thrombin peak or ETP performed at low tissue factor and phospholipid concentrations should be used to evaluate emicizumab activity. Thromboelastometry clotting time is valuable when performed without exogenous triggers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.